Physician profile
Mark Rugarber
NPI 1326619669
$3,753.27
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $340 · 2022: $913 · 2023: $1,053 · 2024: $1,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,500.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $831.26 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $627.50 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $462.56 | 2022-2024 | |
| Lilly USA, LLC | $333.18 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $332.94 | 2021-2022 | |
| Glaxosmithkline, LLC. | $307.61 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $224.67 | 2022-2024 | |
| Astellas Pharma US INC | $114.14 | 2023-2024 | Veozah |
| Merck Sharp & Dohme LLC | $73.05 | 2022-2024 | Gardasil 9, Gardasil, Capvaxive |
| Viiv Healthcare Company | $54.51 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.43 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.18 | 2021-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.72 | 2022-2023 | Jardiance, Tradjenta |
| Axsome Therapeutics, INC. | $34.77 | 2024 | Auvelity |
| Sanofi-Aventis U.S. LLC | $32.36 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $29.76 | 2024 | Unithroid |
| Exact Sciences Corporation | $24.41 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $23.54 | 2024 | Trintellix |
| Phathom Pharmaceuticals, INC. | $22.67 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $20.94 | 2023 | Eliquis |
| Esperion Therapeutics, INC. | $19.02 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.17 | 2023 | Quviviq |
| Abbott Laboratories | $15.55 | 2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rugarber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.